Heatwurx (NASDAQ:PCSA – Get Free Report) and Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability and analyst recommendations.
Valuation & Earnings
This table compares Heatwurx and Nektar Therapeutics”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Heatwurx | N/A | N/A | -$13.56 million | ($9.29) | -0.30 |
| Nektar Therapeutics | $55.63 million | 35.91 | -$164.08 million | ($8.42) | -7.02 |
Analyst Recommendations
This is a summary of recent ratings and recommmendations for Heatwurx and Nektar Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Heatwurx | 1 | 1 | 1 | 0 | 2.00 |
| Nektar Therapeutics | 1 | 1 | 9 | 0 | 2.73 |
Heatwurx presently has a consensus target price of $25.00, suggesting a potential upside of 807.44%. Nektar Therapeutics has a consensus target price of $149.63, suggesting a potential upside of 153.05%. Given Heatwurx’s higher possible upside, equities analysts clearly believe Heatwurx is more favorable than Nektar Therapeutics.
Institutional and Insider Ownership
91.9% of Heatwurx shares are held by institutional investors. Comparatively, 75.9% of Nektar Therapeutics shares are held by institutional investors. 2.4% of Heatwurx shares are held by insiders. Comparatively, 2.5% of Nektar Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Risk & Volatility
Heatwurx has a beta of 1, meaning that its stock price has a similar volatility profile to the S&P 500.Comparatively, Nektar Therapeutics has a beta of 1.14, meaning that its stock price is 14% more volatile than the S&P 500.
Profitability
This table compares Heatwurx and Nektar Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Heatwurx | N/A | -281.31% | -200.80% |
| Nektar Therapeutics | -284.18% | -85.40% | -39.99% |
Summary
Nektar Therapeutics beats Heatwurx on 8 of the 13 factors compared between the two stocks.
About Heatwurx
Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company's pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical trials to treat pancreatic, biliary tract, lung, ovarian, breast, and other cancers; Capecitabine, a combination of PCS6422 and capecitabine that has completed Phase 1b clinical trials to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; and Irinotecan, PCS11T that is in pre-clinical studies to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers. It also develops non-oncology drugs consisting of PCS12852 for treatment of gastroparesis; and PCS499 to treat patients with ulcerative and non-ulcerative necrobiosis lipoidica. The company has license agreements with Elion Oncology, Inc.; Ocuphire Pharma, Inc.; Aposense, Ltd.; Yuhan Corporation; and CoNCERT Pharmaceuticals, Inc. Processa Pharmaceuticals, Inc. was founded in 2011 and is based in Hanover, Maryland.
About Nektar Therapeutics
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.
Receive News & Ratings for Heatwurx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heatwurx and related companies with MarketBeat.com's FREE daily email newsletter.
